1. Home
  2. LCTX vs EDD Comparison

LCTX vs EDD Comparison

Compare LCTX & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$6.05

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
EDD
Founded
1990
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
366.2M
397.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
LCTX
EDD
Price
$1.95
$6.05
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
1.2M
441.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.52%
EPS Growth
25.00
N/A
EPS
N/A
N/A
Revenue
$9,499,000.00
N/A
Revenue This Year
$6.32
N/A
Revenue Next Year
$124.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.19
N/A
52 Week Low
$0.37
$4.28
52 Week High
$2.09
$6.18

Technical Indicators

Market Signals
Indicator
LCTX
EDD
Relative Strength Index (RSI) 64.30 60.25
Support Level $1.55 $5.45
Resistance Level $2.04 $6.18
Average True Range (ATR) 0.11 0.07
MACD 0.02 -0.02
Stochastic Oscillator 89.04 43.59

Price Performance

Historical Comparison
LCTX
EDD

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

Share on Social Networks: